How COVID-19 affects cancer and cardiovascular disease
Keywords:
COVID-19, cardiovascular disease, cancer, mechanism of COVID-19Abstract
After Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was introduced to the world in December 2019, it rapidly continues its journey to more than 185 countries/regions throughout the world in just only a few months1. Due to its powerful transmission capacity, WHO declared COVID-19 a pandemic in March 2020. While the knowledge about risk and its impact is still limited, recent data has shown an association between COVID-19 and the world’s two most common diseases; cardiovascular disease and cancer. Data suggested that these patients are not only more susceptible to SARS-CoV-2 infection, but also likely to develop severe form of disease with higher mortality rate. It is significantly importance to understand the underlying mechanisms of SARS-CoV-2 in order to treat these patients. The purpose of this article is to review current data on the incidence, proposed mechanisms and impacts of COVID-19 among patients with cardiovascular disease and cancer.
References
World Health Organization. Coronavirus. WHO Coronavirus disease (COVID-19) outbreak situation. Accessed April 20, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Chan J, Ng C, Chan Y, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):686-689. https://doi.org/10.1136/thorax.58.8.686
Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2016;49:129-133. https://doi.org/10.1016/j.ijid.2016.06.015
Ganatra S, Hammond SP, Nohria A. The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer. Jacc Cardiooncology. 2020;2(2):350-355. https://doi.org/10.1016/j.jaccao.2020.03.001
Feng R-M, Zong Y-N, Cao S-M, Xu R-H. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun. 2019;39. https://doi.org/10.1186/s40880-019-0368-6
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059. https://doi.org/10.1001/jama.2020.6775
Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. Published online March 26, 2020. https://doi.org/10.1016/j.annonc.2020.03.296
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337. https://doi.org/10.1016/S1470-2045(20)30096-6
World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 16- 24 February 2020. Accessed March 9, 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. https://doi.org/10.1038/s41569-020-0360-5
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 2020;395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020;14(3):247-250. https://doi.org/10.1016/j.dsx.2020.03.013
Chen D, Li X, Song Q, Hu C, Su F, Dai J. Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19). medRxiv. Published online February 29, 2020:2020.02.27.20028530. https://doi.org/10.1101/2020.02.27.20028530
Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med CCLM. 2020;58(7):1131-1134. https://doi.org/10.1515/cclm-2020-0198
Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Published online March 27, 2020. https://doi.org/10.1001/jamacardio.2020.1017
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. https://doi.org/10.1001/jama.2020.1585
Wu Q, Zhou L, Sun X, et al. Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. Sci Rep. 2017;7(1):9110. https://doi.org/10.1038/s41598-017-09536-z
American College of Cardiology. ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19). American College of Cardiology. Accessed March 20, 2020. https://www.acc.org/latest-in-cardiology/articles/2020/02/13/12/42/acc-clinical-bulletin-focuses-on-cardiac-implications-of-coronavirus-2019-ncov
Kirkpatrick JN, Mitchell C, Taub C, Kort S, Hung J, Swaminathan M. ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak: Endorsed by the American College of Cardiology. J Am Soc Echocardiogr. 2020;33(6):648-653. https://doi.org/10.1016/j.echo.2020.04.001
American College of Cardiology. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. American College of Cardiology. Accessed March 23, 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19
European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. European Society of Cardiology. Accessed March 27, 2020. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
Downloads
Published
How to Cite
Issue
Section
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของราชวิทยาลัยจุฬาภรณ์
ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับราชวิทยาลัยจุฬาภรณ์ และคณาจารย์ท่านอื่น ในราชวิทยาลัยฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใด ๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
